- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Multispecies probiotics do not prevent antibiotic-associated diarrhea in children: JAMA
Netherlands: A new study published in the Journal of American Medical Association -- Pediatrics found that multispecies probiotics did not lower the risk of antibiotic-associated diarrhea (AAD) in kids but, decreased the overall risk of diarrhea both during and for seven days after receiving antibiotics.
It is yet unknown if multispecies probiotic compositions can effectively stop diarrhea brought on by antibiotics. In order to determine the impact of a multispecies probiotic on the risk of AAD in children, Jan ukasik and colleagues undertook this investigation.
In a multicenter, randomized study was carried out from February 2018 to May 2021. (inpatients and outpatients). Throughout the duration of the intervention, patients were monitored. Age requirements ranged from three months to eighteen years old, and other requirements included written informed permission and recruiting within 24 hours of starting broad-spectrum systemic antibiotics. 350 out of a total of 646 eligible patients that were contacted participated in the experiment. After testing for common diarrheal infections, the main result was AAD, which is defined as 3 or more loose or watery stools per day in a 24-hour period, either caused by Clostridioides difficile or of another unknown origin. Diarrhea of any cause, its duration, and specific diarrhea complications were among the secondary outcomes.
The key findings of this study were:
1. 350 kids were randomized, 313 of whom were included in the intention-to-treat analysis (192 males and 158 girls; mean age, 50 months).
2. Probiotic (n = 158) had no impact on risk of AAD compared to placebo (n = 155).
3. Regardless of the cause, children in the probiotic group had a decreased probability of developing diarrhea.
4. For the majority of the secondary outcomes, including adverse events, there were no differences between the groups.
In conclusion, using the researched probiotic to reduce diarrhea in kids receiving antibiotic therapy is a possibility. This study also demonstrates that clinical trial results and their interpretation are significantly impacted by the AAD outcome criteria.
Reference:
Åukasik J, Dierikx T, Besseling-van der Vaart I, de Meij T, Szajewska H, Multispecies Probiotic in AAD Study Group. Multispecies Probiotic for the Prevention of Antibiotic-Associated Diarrhea in Children: A Randomized Clinical Trial. JAMA Pediatr. 2022;176(9):860ā866. doi:10.1001/jamapediatrics.2022.1973
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelorās. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751